|
Russia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Russia Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Russia .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Russian pharmaceutical and healthcare industry.
Competitive intelligence, Russian pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Russian market.
The Russia Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Russia Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Russian pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Russia to test other views – a key input for successful budgeting and strategic business planning in the Russian pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Russian Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Russia .
- Exploit The Latest Competitive Russian Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Russia .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Russia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Russia Political SWOT |
| Russia Economic SWOT |
| Russia Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Business Environment Ratings |
| Limits of Potential Returns |
| Risk to Realisation of Returns |
Chapter - Russia – Market Summary |
| Regulatory Regime |
| Intellectual Property Environment |
| Pricing and Reimbursement Issues |
Chapter - Industry Developments |
| Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Russia's Drug Market Expenditure Data And Forecasts, 2006 – 2013 |
| Key Growth Factors – Industry |
| Key Growth Factors – Macroeconomic |
| Tab.e: Russia - Economic Activity |
| OTC Market Forecast |
| Table: Russia's OTC Market Data And Forecasts, 2006-2013 (US$mn unless otherwise stated) |
| Prescription Market Forecast |
| Table: Russia's Prescription Market Data And Forecasts, 2006-2013 (US$mn unless otherwise stated) |
| Generics Market Forecast |
| Table: Russia's Generics Market Data And Forecasts, 2006-2013 |
| Export/Import Forecasts |
| Table: Russia's Pharmaceuticals Exports And Imports Data And Forecasts, 2006-2013 (US$mn) |
| Medical Devices |
| Table: Russia's Medical Device Market Data And Forecasts, 2006-2013 (US$bn unless otherwise stated) |
| Other Healthcare Data Forecasts |
| Table: Russia's Healthcare Data And Forecasts, 2006-2013 |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Manufacturing Sector |
| Wholesale Sector |
| Retail Sector |
| Table: Pharmacies And Pharmacy Market Ratios, 2004-2009 |
Chapter - Company Monitor |
| Berlin-Chemie/Menarini Pharma GmbH |
| Gedeon Richter |
| Krka |
| Lek (Novartis/Sandoz) |
| Stada AG (Stada CIS) |
| Verofarm |
Chapter - Country Snapshot: Russia Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Wages, 2000-2006 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Russia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
As Russia’s economy slows painfully over the course of 2009 and the devalued rouble makes imports more costly, the pharmaceutical market will experience a double-digit US dollar loss, following eight straight years of robust growth. There is disagreement as to how much the Russian economy will shrink in 2009 – BMI believes it will, by 4.0%, while official forecasts see a 2.2% fall. As bad as 2009 looks, BMI forecasts compound an average annual growth rate (CAGR) of 5.62% in US dollar terms for the period 2008 to 2013, with growth hitting 18.7% in 2011 on the back of a broader economic recovery and expected uptick in commodities prices.
Russia’s government is relying on financial stimulus and the strength of the country’s stability fund – put aside during the recent oil price boom – to see it through the worst of the crisis in 2009 and cover the country’s budget deficit. Quixotically, but perhaps effectively, at the beginning of the year the government published a list of companies that were ‘system forming’ or critical to the economy, which included a handful of key pharmaceutical-sector companies. Also critical for the industry is that thus far the banking system, a long-term weak point in the economy, is still functioning, even if credit is scarce. The rouble has devalued, but the government’s risky defence of the currency and its managed devaluation during Q109 has worked – for now.
In the healthcare sphere the government has sought to reassure an increasingly restive population, and a statement by President Dmitry Medvedev in March stated that it will continue to deliver on healthcare and social-sector reforms, although cash strapped regions have threatened to pull out. These reforms include the new mandatory medicines insurance programme promised by 2010, designed to provide the first comprehensive medicines coverage for the wider population since the Soviet era. The state is also seeking to extract cost savings through such measures as delaying tenders for medicines under the supplementary medicines scheme (DLO) and, in March, threatening new price controls on essential medicines. In a more sinister move, the government warned local market monitoring firm DSM that it could be violating the law by forecasting future price rises on medicines, as official statistics measured a 5.2% increase in average medicines prices in February.
Among companies, the Pharmacy Chain 36.6 group has attracted the most headlines recently – as the largest retail pharmacy chain it has now moved to cut out distributors and go directly to major suppliers to control costs. This follows a high profile spat with distributors SIA International and Protek over payment terms. Meanwhile, the group’s Verofarm production asset, with a strong generic oncology as well as plasters franchise, has attracted at least five bidders – including Germany’s Stada – as its longawaited sale could net US$230mn. Local producer Valenta indicated it would sell a stake in its business to fund further production. Among foreign players, Gedeon Richter has said that it is providing financial aid to local distributors in both Russia and Ukraine to help them through the crisis.
|
Russia Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |